Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
International Journal of Clinical Pharmacology and Therapeutics
|
April 25, 2015
Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy
Björn Ställberg, Ian Naya, Jan Ekelund, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 12, 2010
Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea
Mikael Adner, Bengt Larsson, Jesper Säfholm, et al.
Respiratory Research
|
March 28, 2019
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
Ian Naya, Lee Tombs, David A Lipson, et al.
Pulmonary Pharmacology & Therapeutics
|
May 17, 2019
Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials
Riju Ray, Lee Tombs, Ian Naya, et al.
Respiratory Research
|
May 10, 2017
Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis
Yogesh Suresh Punekar, Sheetal Sharma, Ankit Pahwa, et al.
Advances in Therapy
|
November 1, 2016
Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
M Reza Maleki-Yazdi, Dave Singh, Antonio Anzueto, et al.
Journal of Medical Economics
|
August 27, 2016
Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study
Yogesh Suresh Punekar, Ian Naya, Mark Small, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
July 23, 2016
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
Dave Singh, M Reza Maleki-Yazdi, Lee Tombs, et al.
Pulmonary Therapy
|
February 7, 2020
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β<sub>2</sub>-Agonist (LABA) Combinations in COPD
Katya Y J Sion, Eline L Huisman, Yogesh S Punekar, et al.
Respiratory Medicine
|
December 5, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
Maurice Driessen, Dhvani Shah, Nancy Risebrough, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
International Journal of Clinical Pharmacology and Therapeutics
|
April 25, 2015
Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy
Björn Ställberg, Ian Naya, Jan Ekelund, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 12, 2010
Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea
Mikael Adner, Bengt Larsson, Jesper Säfholm, et al.
Respiratory Research
|
March 28, 2019
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
Ian Naya, Lee Tombs, David A Lipson, et al.
Pulmonary Pharmacology & Therapeutics
|
May 17, 2019
Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials
Riju Ray, Lee Tombs, Ian Naya, et al.
Respiratory Research
|
May 10, 2017
Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis
Yogesh Suresh Punekar, Sheetal Sharma, Ankit Pahwa, et al.
Advances in Therapy
|
November 1, 2016
Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials
M Reza Maleki-Yazdi, Dave Singh, Antonio Anzueto, et al.
Journal of Medical Economics
|
August 27, 2016
Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study
Yogesh Suresh Punekar, Ian Naya, Mark Small, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
July 23, 2016
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
Dave Singh, M Reza Maleki-Yazdi, Lee Tombs, et al.
Pulmonary Therapy
|
February 7, 2020
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β<sub>2</sub>-Agonist (LABA) Combinations in COPD
Katya Y J Sion, Eline L Huisman, Yogesh S Punekar, et al.
Respiratory Medicine
|
December 5, 2018
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
Maurice Driessen, Dhvani Shah, Nancy Risebrough, et al.
Page
of 3